Solange Peters

European Society for Medical Oncology — Switzerland

Medicine · Health Sciences

112h-index69.6kcitations931works7.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(396), Cancer Immunotherapy and Biomarkers(209), Lung Cancer Diagnosis and Treatment(173), Lung Cancer Research Studies(165), Cancer Genomics and Diagnostics(143)

Publications910 total

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real‐World Data
Clinical Pharmacology & Therapeutics·2026Open Access
Correction: Does the “Where” Matter? School-Based Pre-K Versus Center-Based Pre-K and its Link to Students’ Absenteeism
Early Childhood Education Journal·2025Open Access
Assessing Tumour Budding in Lung Squamous Cell Carcinoma: A Comparative Analysis of Digital Whole-Slide Imaging and Light Microscopy
Pathobiology·2025Open Access
Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma
Annals of Oncology·2025· 2 citedOpen Access
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
Clinical Cancer Research·2025Open Access
Quality improvement report: Investigating barriers in <scp>HIV</scp> testing oncology patients to optimize <scp>HIV</scp> testing practice
HIV Medicine·2025· 1 citedOpen Access
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
ESMO Open·2025Open Access
The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness‐Based Cancer Recovery (e‐MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial
Psycho-Oncology·2025Open Access
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons
ESMO Open·2025Open Access
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
Annals of Oncology·2025· 4 citedOpen Access
OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Journal of Thoracic Oncology·2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
The Lancet Oncology·2025· 9 cited
MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study
Journal of Thoracic Oncology·2025
SY11-1 Treatment for EGFR-mutated patients after EGFR-TKI failure
Annals of Oncology·2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Nature Communications·2025Open Access
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC
JTO Clinical and Research Reports·2025Open Access
LBA73 Final overall survival (OS) and safety analysis of the phase III ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Annals of Oncology·2025Open Access
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology·2025· 26 citedOpen Access
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Cancer·2025
Interpreting immunogenicity in oncology clinical trials
Cancer Treatment Reviews·2025Open Access
page 1 of 46Next →

Frequent Co-authors

Enriqueta Felip(12), Tony Mok(12), Keith M. Kerr(11), Luis Paz‐Ares(8), Martin Reck(8), Corinne Faivre‐Finn(8), Suresh Senan(7), Rolf A. Stahel(7), Benjamin Besse(7), Fabrice Barlési(6), Silvia Novello(6), Sanjay Popat(6), Egbert F. Smit(6), Antonio Passaro(6), Dirk De Ruysscher(6), Martin Früh(6), Shirish M. Gadgeel(5), Karin Jordan(5), Martin Reck(5), Julien Mazières(5)